Tesamorelin + Retatrutide: Should You Stack Them for Fat Loss
A clinic-based coach argues that tesamorelin and retatrutide target different pathways of metabolic disease, and explains how his practice sequences them and who he thinks should consider both.
With Dr. Jones, DC (DC)
Key moments
Tap a moment to play the video from there.
- 0:00Reframing the stacking questionDr. Jones says the real question is whether the stack can contribute to reversing metabolic disease, not whether it speeds fat loss. He introduces himself and his own weight loss story.
- 1:13Visceral fat and the insulin spiralHe describes visceral fat as metabolically active and inflammatory, and says it feeds a cycle with insulin resistance and fatty liver.
- 2:39Muscle loss on unstructured GLP-1sHe says patients who lose 20 to 50 lbs on their own often lose muscle, keep high body fat percentage, and see little change in visceral fat or liver markers.
- 3:28How tesamorelin worksHe explains that tesamorelin is a GHRH analog, FDA approved for HIV associated lipodystrophy, that raises the body's own growth hormone and, he says, favors visceral fat loss. He gives his clinic's evening, off-label timing.
- 6:19Retatrutide and the glucagon receptorHe contrasts retatrutide's three receptors with semaglutide and tirzepatide, explains glucagon as a release hormone, and cites a phase two trial result for weight and liver fat.
- 8:36Why the two work in parallelHe says retatrutide addresses insulin resistance and metabolic flexibility while tesamorelin goes after visceral fat through growth hormone and IGF. He adds that most people probably do not need both.
- 11:18Sequencing and dosing in his clinicHe advises against starting both at once, says to stabilize on one drug first, then add tesamorelin. He gives his clinic's tesamorelin schedule and stresses protein, training and fasting windows.
- 12:50Who he thinks the stack suitsHe lists people with significant visceral fat, documented insulin resistance or fatty liver, and health optimizers, and says optimizers may need only 1 to 2 mg of retatrutide.
- 14:16Takeaways and clinic invitationHe recaps the two pathways and invites viewers to book a free discovery call with his practice, then points to a separate video on retatrutide stacking.
What the video says
Dr. Jones, DC, who says he coaches patients on GLP-1s and peptides through a medical practice, reframes the question of stacking tesamorelin with retatrutide. He says it is less about faster fat loss and more about whether the pair can contribute to reversing metabolic disease. He builds the case around visceral fat, insulin resistance and fatty liver, and says patients who lose weight on GLP-1s without structure can lose a lot of muscle while visceral fat and markers such as liver enzymes stay high.
On tesamorelin, he describes a growth hormone releasing hormone analog that is FDA approved for HIV associated lipodystrophy and used off-label by his clinic in other patients. He says it prompts the pituitary to release the body's own growth hormone, and that growth hormone signaling shrinks visceral fat more than other fat depots, so waist size can drop even when weight loss is modest. For retatrutide, he stresses the glucagon receptor on top of GLP-1 and GIP. He describes glucagon as a release hormone that pushes the body toward mobilizing stored energy, and he cites a phase two trial with about 24% weight loss at 48 weeks and an 82% reduction in liver fat.
Dr. Jones says the two compounds run on parallel tracks, growth hormone and IGF on one side and glucagon on the other. He also says most people probably do not need both, and that tirzepatide alone is very powerful. On sequencing, he warns against starting everything on day one, recommends establishing a baseline on one drug for a minimum of two to four weeks, then adding tesamorelin. He gives his clinic's tesamorelin dosing as 500 to 1,000 micrograms, 5 days on and 2 days off, taken before bed away from food. He calls protein, resistance training and fasting windows non-negotiable.
He names the people he sees as suited to the stack: those with significant visceral fat, documented insulin resistance or fatty liver, and health optimizers. The video also includes repeated invitations to book a discovery call with his practice, so it is partly a promotion for that service.
On each compound
Tesamorelin3:28
Dr. Jones describes tesamorelin as a GHRH analog that stimulates the pituitary to release more of the body's own growth hormone. He says it disproportionately reduces visceral fat, and that his clinic uses 500 to 1,000 micrograms, 5 days on and 2 days off, before bed.
See how your DNA reads TesamorelinRetatrutide6:19
Dr. Jones says retatrutide acts on GLP-1, GIP and glucagon receptors and that the glucagon piece shifts the body toward mobilizing stored energy. He cites a phase two trial with about 24% weight loss at 48 weeks and an 82% reduction in liver fat.
See how your DNA reads RetatrutideTirzepatide11:18
Dr. Jones says tirzepatide alone is very powerful and that his clinic starts patients on it first to set a baseline before adding tesamorelin. The captions are inconsistent here, as he elsewhere refers to starting with retatrutide.
See how your DNA reads Tirzepatide“They're running on completely parallel tracks.”
What this video doesn’t settle
- The video gives no trial evidence for combining tesamorelin with retatrutide itself, only separate claims about each compound and the speaker's clinic experience.
- Tesamorelin doses and cycling schedules are described as the clinic's off-label practice, without supporting data or a comparison to the FDA label dosing.
- The captions are inconsistent about whether patients start with tirzepatide or retatrutide, so the intended first drug in the sequence is unclear.
Questions this video answers
Why does Dr. Jones say tesamorelin differs from other fat loss tools?
He says tesamorelin raises the body's own growth hormone and that growth hormone signaling reduces visceral fat more than other fat depots. He says he has seen waist measurements fall significantly even when overall weight loss was modest.
What does Dr. Jones say the glucagon receptor adds to retatrutide?
He describes glucagon as a release hormone that tells the liver to put stored energy back into circulation, raises fat breakdown and promotes ketone production. He says this resembles aspects of a prolonged fasting state and likely improves metabolic flexibility.
How does Dr. Jones recommend sequencing tesamorelin with a GLP-1 drug?
He says not to start both on the same day, so any change or side effect can be traced to one compound. In his clinic, patients establish a baseline on the GLP-1 drug for a minimum of two to four weeks before tesamorelin is added.
Does Dr. Jones say everyone needs both tesamorelin and retatrutide?
No. He says that for most people, probably not, and that tirzepatide alone is very powerful. He sees the stack as suited to people with significant visceral fat, documented insulin resistance or fatty liver, and to health optimizers.
Video by Dr. Jones, DC on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
